Skip to main content

Table 1 Patients’ characteristics

From: SIVA, a target of p53, is downregulated in myelodysplastic syndromes

Patients

Number

MDS

55

Gender

 Male/Female

32/23

Age (years), median (range):

69 (16–90)

WHO classification

 RA/RARS/RCMD

3/4/31

 RAEB-1/RAEB-2

10/7

IPSS-R

 Very low/Low

7/25

 Intermediate/High/Very high

8/9/4

 Not available

3

Cytogenetic riska

 Very good/good

2/42

 Intermediate

6

 Poor /very poor

0/2

 No growth

3

BM blast (%)

 < 5%

38

 ≥ 5 and <10%

10

 ≥ 10 and <20%

7

  1. Abbreviations: MDS myelodysplastic syndromes, WHO World Health Organization, RA refractory anemia, RARS refractory anemia with ringed sideroblasts, RCMD refractory cytopenia with multilineage dysplasia, RAEB-1 refractory anemia with excess blast-1, RAEB-2 refractory anemia with excess blast-2, BM bone marrow
  2. aIn MDS cohort, karyotype findings included very low risk: –Y (n = 1), del(11q) (n = 1); low risk: normal (n = 46), intermediate risk: +8 (n = 2); −7 (n = 1), other (n = 3); high risk: 3 abnormalities (n = 0), and very high risk: >3 abnormalities (n = 2)
Back to article page

Applied Cancer Research

ISSN: 1980-5578